| Literature DB >> 28596916 |
Cunyang Wang1, Yan Liu1,2, Yubo Fan1, Xiaoming Li1,3.
Abstract
It has been well recognized that the modification of biomaterials with appropriate bioactive peptides could further enhance their functions. Especially, it has been shown that peptide-modified bone repair materials could promote new bone formation more efficiently compared with conventional ones. The purpose of this article is to give a general review of recent studies on bioactive peptide-modified materials for bone tissue repair. Firstly, the main peptides for inducing bone regeneration and commonly used methods to prepare peptide-modified bone repair materials are introduced. Then, current in vitro and in vivo research progress of peptide-modified composites used as potential bone repair materials are reviewed and discussed. Generally speaking, the recent related studies have fully suggested that the modification of bone repair materials with osteogenic-related peptides provide promising strategies for the development of bioactive materials and substrates for enhanced bone regeneration and the therapy of bone tissue diseases. Furthermore, we have proposed some research trends in the conclusion and perspectives part.Entities:
Keywords: bone repair material; osteogenic activity; peptide
Year: 2017 PMID: 28596916 PMCID: PMC5458541 DOI: 10.1093/rb/rbx011
Source DB: PubMed Journal: Regen Biomater ISSN: 2056-3426
In Vitro and in vivo studies presenting the osteogenic effects of ECM-derived peptides
| Active peptides | Abbreviation | Composition | Binding sites | Upregulation / Downregulation of proteins or genes | Final functions | References |
|---|---|---|---|---|---|---|
| PepGen P-15 | P-15 | 15 amino acids | type I collagens-binding sites | upregulating the expression of ALP, BMP-2, BMP-7; RUNX2, COL1, OSTRX and BSP; a2 integrin | upregulating proliferation and osteogenic differentiation; cell attachment, migration and survival; extracellular matrix production | 14–16, 20 |
| arginyl-glycyl- aspartic acid | RGD | 3 amino acids | integrin-binding sites | upregulating the expression of ALP, RUNX2, osteocalcin, osteopontin and BSP; Sox9, Aggrecan, fibronectin and clloagen II | upregulation proliferation; osteogenic differentiation and mineralization; cell attachment and survival | 21–25 |
| Ser-Val-Val-Tyr- Gly-Leu-Arg | SVVYGLR | 7 amino acids | RGD-binding sites | upregulating αvβ3 integrin; suppressing NFAT activity and expression of osteoclastogenesis-related mRNAs | upregulating proliferation and neovascularization; angiogenesis and osteogenesis; adhesion, migration and tube formation of endothelial cells | 26–28 |
| glycine-phenylalanine- hydroxyproline-arginine | GFOGER | 4 amino acids | α2β1 integrin-binding sites | upregulating α2β1 integrin binding | upregulating differentiation, bone regeneration and osseointegration | 29–32 |
| Asp-Gly-Glu-Ala | DGEA | 4 amino acids | α2β1 integrin-binding sites | upregulating ALP | cell adhesion, spreading and osteogenic differentiation | 33–37 |
| collagen-binding motif | CBM | 28 amino acids | collagen-binding sites | inducing sustained activation of ERK; the transactivation of SRE, CRE, and AP-1; expression of type X collagen | upregulating bone-related cell adhesion and growth; osteogenic differentiation | 38–39 |
| lysine-arginine- serine-arginine | KRSR | 4 amino acids | heparin-binding sites | upregulating osteogenic gene expression | upregulating bone-related cell spreading, adhesion and mineralization | 40–46 |
| Phe-His-Arg-Arg- Ile-Lys-Ala | FHRRIKA | 10 amino acids | putative heparin-binding sites | – | upregulating bone-related cell spreading, adhesion and mineralization | 47, 48 |
| Fibronectin-derived peptides | FN-derived peptides | 7 amino acids | – | – | upregulating bone-related cell spreading, adhesion and mineralization | 49–51 |
In Vitro and in vivo studies presenting the osteogenic effects of other peptides except those derived from ECM and BMPs
| Active peptides | Abbreviation | Composition | Potential pathways | Upregulation / Downregulation of proteins or genes | Final functions | References |
|---|---|---|---|---|---|---|
| calcitonin gene-related peptides | CGRP | 37 amino acids | the cAMP, Wnt and AMPK-eNOS pathways | upregulating expression of IGF-1, IGF-1 receptor and BMP-2 receptor; ALP, OC and COLLA1 | upregulating cell proliferation, osteogenic differentiation and angiogenesis; downregulating apoptosis and inflammation | 67-85 |
| Parathyroid hormone (1-34) | PTH1-34 | 34 amino acids | G(q)-signalling, β-arrestin recruitment, ERK1/2 phosphorylation and phospholipase C pathway | upregulating expression of Runx2 and COL2A1; downregulating expression of ALP and BMP-2 | upregulating cell proliferation and chondrogenesis | 86-88 |
| osteogenic growth peptides | OGP | 14 amino acids | the G1 protein-MAPK and RhoA/ROCK pathway | upregulating osteocalcin, collagen, BMP-2, ALP and mineralization; upregulating TGF β1, β2, β3, FGF-2, IGF-I | upregulating cell proligeration and osteogenic differentiation; cartilage-to-bone transition; downregulating adipogenic differentiation | 89-96 |
| thrombin peptide 508 | TP508 | 23 amino acids | cell cycle-G1/S checkpoint, JAK/STAT, NF-kappaB, PDGF, PI3K/AKT, PTEN, and ERK/MAPK | upregulating the expression of Runx2 and OPN | upregulating cell proliferation and osteogenic differentiation; chemotaxis, angiogenesis and revascularization; downregulating apoptosis, the effect of hypoxia | 22, 97-99 |
| NEMO-binding domain peptide | NBD | 6 amino acids | NF-κB pathway | downregulating TRAP activity, actin rings; RANKL-induced c-Src kinase activity | upregulating osteogenic differentiation of cells; downregulating bone resorption | 100-103 |
| Cell penetrating peptide | CPP | 30 amino acids | – | – | transcriptional factor to deliver bone-regenerating related proteins or factors into cells | 104-106 |
| AcN-RADARADARADARADA-CONH2 | RADA16-I | 16 amino acids | – | upregulating expression of Runx2 genes, ALP and osteocalcin | transcriptional factor to deliver bone-regenerating related proteins or factors into cells | 107-109 |
Figure 1.(a) Process illustration of covalent immobilization of the RGD peptide on Ti bone repair material by electrodeposition, (b) simple description of the difference between RGD/PEG/Ti and RGD/Ti materials (adapted with permission from ref. [17]. Copyright 2011 Elsevier Ltd)
Figure 2.Preparation of poly(glycidyl methacrylate)-polyurethane acrylate (pGMA-PUA) nanopatterned substrate materials. pGMA was deposited onto the PUA substrates via the initiated chemical vapor deposition (iCVD) polymerization process, which was synthesized with GMA monomer and initiator (TBPO) (adapted with permission from ref. [62]. Copyright 2013 Elsevier Ltd)
Figure 3.Compared to untreated titanium (Ti), GFOGER peptide coated Ti much more significantly promoted specific osteogenic gene expression (a), enhanced ALP activity (B) and biomineralization (C) of the cultured bone marrow stromal cells (adapted with permission from ref. [29]. Copyright 2007 Elsevier Ltd)
Figure 4.Alizarin red staining images of ABM/hy(a) and ABM/P-15/hy (B) cultured with HOS cells for 2 weeks. Bar =500 μm (adapted with permission from ref. [20]. Copyright 2003 Elsevier Ltd)
Figure 5.ALP Activity of MG-63 cells cultured on pure PAS and peptide-modified PAS with different incorporated concentrations for 7 and 14 days (adapted with permission from ref. [124]. Copyright 2016 Elsevier Ltd)
Figure 6.CT Images of P24/PLGA-(PEG-ASP)n (a-d), PLGA-(PEG-ASP)n (e), and gelatin sponge (f) after implanted into the dorsal muscle of rats for 12 weeks after operation. Arrows indicated the new bone formation (adapted with permission from ref. [63]. Copyright 2010 Elsevier Ltd)
Figure 7.The histological images of the implanted materials at two time points: (a) P24/TBC/collagen I, (c) TBC/collagen I, (e) TBC at 8 weeks; (b) P24/TBC/collagen I, (d) TBC/collagen I, and (f) TBC at 12 weeks (magnification: 200×) (adapted with permission from ref. [125]. Copyright 2010 Elsevier Ltd)